Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT05041127

Collaborator

(none)

Enrollment

Location

Arm

27.2

Anticipated Duration (Months)

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.

Condition or Disease	Intervention/Treatment	Phase
Chordoma Metastatic Chordoma Unresectable Chordoma	Biological: Cetuximab Other: Questionnaire Administration	Phase 2

Detailed Description

Primary Objective:

• To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or metastatic, chordoma based on response rate according to RECIST1.1.

Secondary Objectives:

To evaluate response rate according to Choi criteria
To evaluate the safety and tolerability of cetuximab for chordoma patients
To evaluate the progression-free survival (median, at 24 weeks, and 52 weeks) and to determine the overall survival (median).
To evaluate the ratio of PFS on study compared to PFS from prior treatment

Study Design

Study Type:

Interventional

Anticipated Enrollment :

15 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Trial of Cetuximab for Patients With Advanced or Metastatic Chordoma

Actual Study Start Date :

May 27, 2022

Anticipated Primary Completion Date :

Sep 1, 2024

Anticipated Study Completion Date :

Sep 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (cetuximab) Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.	Biological: Cetuximab Given IV Other Names: Cetuximab Biosimilar CDP-1 Cetuximab Biosimilar CMAB009 Cetuximab Biosimilar KL 140 Chimeric Anti-EGFR Monoclonal Antibody Chimeric MoAb C225 Chimeric Monoclonal Antibody C225 Erbitux IMC-C225 Other: Questionnaire Administration Ancillary studies

Arm

Intervention/Treatment

Experimental: Treatment (cetuximab)

Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.

Biological: Cetuximab

Given IV

Other Names:

Cetuximab Biosimilar CDP-1

Cetuximab Biosimilar CMAB009

Cetuximab Biosimilar KL 140

Chimeric Anti-EGFR Monoclonal Antibody

Chimeric MoAb C225

Chimeric Monoclonal Antibody C225

Erbitux

IMC-C225

Other: Questionnaire Administration

Ancillary studies

Outcome Measures

Primary Outcome Measures

Overall response rate [through study completion, an average of 1 year]
Measured by Response Evaluation Criteria in Solid Tumors 1.1. Will be estimated based on a binomial portion expressed as percentage with 95% confidence intervals.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18 years
Histologically confirmed diagnosis of chordoma which is advanced (unresectable) and/or metastatic
ECOG Performance Status of ≤ 2
At least one site of measurable disease on x-ray/CT/MRI and/or PET/CT scan as defined by RECIST 1.1 criteria. Baseline imaging must be performed within 30 days of Day 1 of study.
Adequate organ function within 28 days of Day 1 of study defined as:
The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥ 1000/L, hemoglobin ≥ 9 g/dL (5.58 mmol/L), and platelets ≥ 100,000/L
The patient has adequate hepatic function as defined by a total bilirubin ≤1.5 mg/dL (25.65 μmol/L) (NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times the upper limit of normal (ULN; or 5.0 times the ULN in the setting of liver metastases).

The patient has adequate renal function as defined by a serum creatinine ≤1.5 times the ULN, or creatinine clearance (measured via 24-hour urine collection) ≥40 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed).

Patients may have any prior line of therapy, but there should a washout period of at least 3 weeks from any systemic therapy (small molecule/targeted agents, immunotherapies) and/or radiation therapy.
Patients should be completely recovered from any reversible toxicities associated with any prior therapies.
There should be access of archival tumor tissue for central pathology review, or a new tumor related biopsy should be considered within acceptable risk to the patient.
Patients must have no prior history of use of an EGFR inhibitor for treatment of their chordoma
Because the teratogenicity of cetuximab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative serum pregnancy test ≤ seven days prior to Day 1 of study.
Life expectancy of > 3 months

Exclusion Criteria:

Prior use of an EGFR inhibitor for treatment of their chordoma
Non-metastatic, resectable disease
No measurable disease according to RECIST 1.1
Life expectancy of less than 3 months
Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured.
Concomitant participation to another clinical trial with active agent during the study (concomitant non-interventional study will be allowed) Patients who have a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab, red meat allergy, or tick bite history
Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
The patient has clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency.
The patient has uncontrolled or poorly-controlled hypertension (>180 mmHg systolic or

130 mmHg diastolic.

Major surgery within 4 weeks prior to Day 1 of study or who have not recovered adequately from prior surgery
Patients who have received wide field radiotherapy ≤ 3 weeks or limited field radiation for palliation < 3 weeks prior to Day 1 of study or who have not recovered adequately from side effects of such therapy
Patients who have received any prior systemic therapy < 3 weeks prior to Day 1 of study or have not recovered adequately from toxicities to the baseline.
Women who are pregnant or nursing/breastfeeding.
Inability to comply with protocol required procedures